Vaccine shows promise as treatment for colorectal, pancreatic cancer
Researchers say a vaccine with a new drug performed well in a clinical trial at preventing the recurrence of pancreatic and colorectal cancer
Source: medicalnewstoday.com
Early Drug Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Early Drug Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Early Drug Development Program Today - Breaking & Trending Today
FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma
Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration.
Source: onclive.com
Dr Hanna on the FDA Approval of Toripalimab in Nasopharyngeal Carcinoma
Glenn J. Hanna, MD, discusses the significance of the FDA approval of toripalimab for patients with recurrent or metastatic nasopharyngeal carcinoma.
Source: onclive.com
Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRC
Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.
Source: onclive.com
Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC
Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.
Source: onclive.com